News | Ventricular Assist Devices (VAD) | June 23, 2022

Medtronic Recalls HeartWare HVAD System Batteries Due to Battery Failure

The FDA has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries or death.

Medtronic, Inc. is recalling a single lot of HeartWare HVAD System batteries due to welding defects that allow separation of the two cell battery packs used to power the system

June 23, 2022 — Medtronic, Inc. is recalling a single lot of HeartWare HVAD System batteries due to welding defects that allow separation of the two cell battery packs used to power the system. The welding defect may cause the battery to malfunction and no longer provide power or prevent the battery from holding a full charge or properly recharging.

The U.S. Food and Drug Administration (FDA) has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries or death.

Recalled Product

  • Product Names: Medtronic HVAD Batteries
  • Product Codes: See Recall Database Entry
  • Model Number: 1650DE
  • Manufacturing Dates: April 13, 2021 to April 19, 2021
  • Distribution Dates: April 20, 2021 to July 19, 2021
  • Devices Recalled in the U.S.: 429
  • Date Initiated by Firm: May 5, 2022

Device Use

The HeartWare Ventricular Assist Device (HVAD) System is used to help the heart continue to pump blood to the rest of the body. The HVAD system is used as a bridge to cardiac transplants in patients who are at risk of death from end-stage left ventricular heart failure, for heart tissue recovery, or as destination therapy (DT) in patients for whom heart transplants are not planned.

Reason for Recall

Medtronic, Inc. is recalling a single lot of HeartWare HVAD System batteries due to welding defects that allow separation of the two cell battery packs used to power the system. The welding defect may cause the battery to malfunction and no longer provide power or prevent the battery from holding a full charge or properly recharging. As a result, the battery may fail suddenly.

If this malfunction occurs, it will trigger a Power Disconnect alarm on the controller screen and in the Alarm Log tab of the HVAD Monitor while the affected battery is still connected to the controller. These alarms may temporarily resolve, but the battery will continue to fail.

The use of these batteries may lead to device malfunction, death, or serious injury.

Medtronic reports one death associated with this recall, and two complaints in the affected lot.

Who May be Affected

  • Health care providers treating patients with the Heartware HVAD System
  • Patients who have the Heartware HVAD System implanted

What to Do

On May 5, 2022, Medtronic sent an Urgent Medical Device Correction letter to all affected customers.

  • Immediately identify and quarantine all affected batteries.
  • Immediately notify patients with affected batteries that Medtronic is conducting this retrieval and have them remove these batteries from service. Medtronic has provided a patient template that may be used to communicate directly with patients.
  • Contact a Medtronic Field Representative to assist you in the return of the affected product.
  • Complete the enclosed Customer Confirmation Form and follow the instructions to initiate an exchange. When complete please return the form to [email protected].
  • Share this notice to all those who need to be aware within your organization or to any organization where the affected batteries has been transferred

Medtronic is replacing the affected batteries with new product and has implemented actions to improve control of the welding process.

Contact Information

Health care providers with questions about this recall should contact their local Medtronic Representative.

Patients with questions about this recall should contact Medtronic Patient Services at 800-635-3930 (Monday-Friday, 8 a.m. to 5 p.m. Central time).

For more information: www.fda.gov

Related HVAD Content:

Medtronic Recalls HVAD Pump Implant Kit for Pump Weld Defect

Medtronic Recalls HVAD Pump Implant Kits After 2 Deaths and 19 Serious Injuries

Class I Recall Issued for Medtronic HeartWare HVAD Pump

Medtronic HeartWare HVAD System Approved for Destination Therapy

FDA, Medtronic Expand HeartWare VAD Recall, Announces New Recall of VAD Component

FDA Announces Two HeartWare HVAD System Class 1 Recalls

New Heart Assist Pump Allows Minimally Invasive Approach at Vanderbilt Heart and Vascular Institute


Related Content

News | Heart Failure

April 16, 2024 — Each year more than 500,000 Americans undergo percutaneous coronary intervention, or PCI, a minimally ...

Home April 16, 2024
Home
News | Heart Failure

April 12, 2024 — University of Virginia School of Medicine researchers have discovered a gene on the Y chromosome that ...

Home April 12, 2024
Home
News | Heart Failure

April 2, 2024 — People who use e-cigarettes are significantly more likely to develop heart failure compared with those ...

Home April 02, 2024
Home
News | Heart Failure

March 29, 2024 — V-Wave announced it will present late-breaking data from its RELIEVE-HF pivotal trial at the American ...

Home March 29, 2024
Home
News | Heart Failure

March 25, 2024 — A team of engineers led by the University of Massachusetts Amherst and including colleagues from the ...

Home March 25, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc. , a biotechnology company focused on advancing late-stage cell therapy interventions ...

Home March 15, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc., a biotechnology company focused on advancing late-stage cell therapy interventions for ...

Home March 15, 2024
Home
News | Heart Failure

March 13, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home March 13, 2024
Home
News | Heart Failure

March 8, 2024 — The Texas Heart Institute, Georgia Institute of Technology (Georgia Tech), North Carolina State ...

Home March 08, 2024
Home
News | Heart Failure

March 5, 2024 — FIRE1 announced that it has completed patient enrollment in the U.S. Early Feasibility Study (FUTURE-HF2 ...

Home March 05, 2024
Home
Subscribe Now